In partnership with

Welcome to this month’s ADVOCATE BRIEF

TEASER:

March buried nothing. It surfaced $664 billion in Medicaid cuts, Medicare Advantage fraud settlements, a transparency rollback at the largest healthcare conglomerate in the country, and an $800 million patient assistance merger that will reshape how millions of Americans access care. If your organization cannot explain where it stands on every one of these issues, April will answer for you.

Spring does not forgive what winter hid

March delivered a month of exposure across every dimension of healthcare: policy, economics, community trust, and technology. Washington confirmed that the largest Medicaid rollback in American history will cost states $664 billion and strip coverage from millions. CMS expanded drug price negotiations while insurers settled fraud claims worth hundreds of millions. Patient advocacy organizations announced a historic merger, and the largest healthcare conglomerate in the country decided that less transparency serves its interests better than more.

I have spent more than two decades inside this industry, and the pattern repeats:

❝

The organizations that get ahead of disruption earn credibility, and the ones that wait for permission get reorganized.

Matt Toresco

This edition breaks down where the ground shifted in March, what it means for commercial strategy and patient access, and what you need to act on before the next cycle starts.

The Tech newsletter for Engineers who want to stay ahead

Tech moves fast, but you're still playing catch-up?

That's exactly why 200K+ engineers working at Google, Meta, and Apple read The Code twice a week.

Here's what you get:

  • Curated tech news that shapes your career - Filtered from thousands of sources so you know what's coming 6 months early.

  • Practical resources you can use immediately - Real tutorials and tools that solve actual engineering problems.

  • Research papers and insights decoded - We break down complex tech so you understand what matters.

All delivered twice a week in just 2 short emails.

Join 200K+ engineers

POLICY PULSE: POLITICAL

Federal and state policymakers forced decisions in March that will reshape patient access for years. The question for advocacy leaders and commercial teams is whether they will drive the response or absorb the consequences.

Key Insights

  • State Medicaid budgets face a $664 billion reduction over the next decade under the One Big Beautiful Bill Act. A RAND analysis confirmed that more than 20 states will absorb cuts exceeding 5% of their current Medicaid budgets. Independent projections estimate 7.6 million Americans will lose coverage. More than 300 rural hospitals sit at immediate closure risk. For pharma commercial teams with Medicaid-dependent patient populations, access models built before this legislation require immediate revision. For patient advocacy organizations, the advocacy crisis of 2026 started in March.

  • Every manufacturer selected for the third cycle of Medicare drug price negotiations chose to participate. CMS named 15 drugs, including cancer, autoimmune, and HIV treatments, marking the first time Part B drugs entered the negotiation framework. Initial offers are due June 1. Negotiated prices take effect in 2028. Companies that spent years litigating against the Inflation Reduction Act now face an operating environment they cannot reverse.

  • A federal judge in Boston blocked Health Secretary Robert F. Kennedy Jr.'s overhaul of childhood vaccine policy, ruling the administration likely violated the Administrative Procedure Act. Patient advocacy organizations fluent in regulatory process hold real structural power. Public comment periods, legal standing, and coalition submissions to regulatory dockets protect evidence-based medicine when politics pushes against it.

  • Senate Democrats circulated a 2026 midterm healthcare platform targeting prior authorization reform, Medicaid protection, insurer accountability, and ACA subsidy extension. Patient advocacy organizations without a federal engagement strategy for this election cycle have already fallen behind the organizations that shaped the conversation.

Policy now moves at the speed of headlines. Advocacy and market access teams that wait for rules to be finalized before building a response will spend the next two years reacting rather than leading.

COST OF CARE: ECONOMIC

The economics of healthcare dominated March in ways that directly affect patient behavior, commercial forecasting, and advocacy credibility. Every number below represents a patient making a harder choice.Text

Key Insights:

  • New federal rules now permit catastrophic health plan deductibles to reach $31,000 in maximum out-of-pocket costs. For patients managing chronic illness, cancer, or rare disease, a plan structure like this functions as a financial wall disguised as coverage. Financial toxicity kills adherence, kills outcomes, and kills trust. Pharma commercial teams need to understand what percentage of their patient populations face catastrophic plan structures. The answer reveals whether patient-centric messaging reflects reality.

  • CVS agreed to pay $118 million to settle allegations that Aetna systematically upcoded Medicare Advantage patient diagnoses to collect higher federal reimbursements. Separately, new analysis showed MA plan overpayments add $212 per enrollee per year to senior premiums, totaling billions annually across 33 million enrollees. Plans profit from inflated diagnoses. Seniors pay more. Advocates serving Medicare populations need operational fluency on MA plan economics.

  • UnitedHealth Group disclosed 3,100 subsidiaries to the SEC last year. This year it disclosed 10. The largest healthcare conglomerate in the United States chose to make it significantly harder for regulators, investors, and the public to understand what the company controls. Less disclosure obscures accountability at every level of the patient experience. Transparency is the minimum standard that makes an accountable system possible.

  • Hospitals report falling biosimilar acquisition costs, but health plans capture only a fraction of those savings. The gap between manufacturer price reductions and patient-level cost reductions reveals where the system absorbs value before it reaches the people who need it. Meanwhile, the top 10 drugs losing U.S. exclusivity in 2026 represent billions in potential savings that may or may not reach patients.

Cost pressure forces every stakeholder to choose between margin and mission. Organizations that claim patient centricity must show, with data, how they reduce friction in affordability. The rest perform theater.

COMMUNITY LENS: SOCIOCULTURAL

Advocacy credibility faced its sharpest test in March. Two organizations controlling $800 million in patient assistance merged. A new platform raised $6.5 million to challenge the status quo. And the power structures patients navigate every day got exposed in ways the advocacy community cannot afford to ignore.

Key Insights

  • The Patient Advocate Foundation and the Patient Access Network Foundation announced a merger combining more than $800 million in resources across 130 disease-specific assistance funds. By July, they will launch a unified platform called Total Assist. The question is: does Total Assist genuinely make it easier for community health workers and advocates to operate on behalf of patients, or does it merely consolidate the same siloed processes under a new name? The advocacy community should engage this merger proactively. The design decisions happening now will shape patient access for years.

  • Baba, a patient advocacy technology platform, made its public debut with $6.5 million in seed funding. New capital entering the advocacy space signals that investors see structural demand for better tools. Whether Baba delivers remains to be seen, but the market signal matters: patient advocacy as a function is attracting serious investment for the first time.

  • A detailed investigation traced the American Hospital Association from eight administrators meeting in Cleveland in 1898 to a $146 million organization spending $29 million annually lobbying Congress and suing twice to block federal price transparency. The AHA represents its members effectively. The persistent confusion between an organization built to protect hospital revenue and one built to protect patients produces policy outcomes that favor institutional margins over patient access.

Community trust erodes when engagement lacks measurable impact. The organizations that integrate advocacy insights into execution and accountability will earn durable credibility. Everyone else continues performing engagement theater while patients wait for something real.

Technology moved fast in March while governance struggled to keep pace. AI entered the exam room, cyberattacks hit manufacturing, and innovation in obesity treatment pushed the boundaries of what patients can access.

Key Insights

  • Stryker confirmed a cyberattack disrupted manufacturing and shipping operations. The breach exposed how fragile the supply chain remains for devices and implants patients depend on. Every advocacy organization serving patients who depend on medical devices should understand how supply chain disruption translates to delayed procedures and compromised care.

  • CMS signaled its intent to deploy AI for senior care navigation. Microsoft launched a health AI chatbot. Amazon expanded its health AI assistant. Three moves in a single month confirming AI will mediate how patients find, access, and manage healthcare. The question for advocacy organizations: who trains these systems, who audits their recommendations, and who advocates for patients when the algorithm gets it wrong?

  • Structure Therapeutics reported clinical trial results for its oral GLP-1 pill showing best-in-class potential for obesity treatment. An oral option removes the injection barrier keeping millions of eligible patients from starting therapy. The access conversation for obesity and type 2 diabetes populations shifts fundamentally. Patient advocacy organizations in metabolic health should prepare for a wave of patient education demand.

Technology expands access and efficiency. It also exposes fragility. Leaders who invest in governance, interoperability, and security with the same urgency they invest in innovation will protect patients. The rest will discover the cost of moving fast without guardrails.

The Ground Thawed In March & Nothing Stayed Buried.

Medicaid faces its largest contraction in history. Medicare Advantage fraud settlements confirm incentive structures that run counter to patient outcomes. The biggest healthcare company in the country reduced its transparency to near zero. Patient assistance organizations merged to serve patients better, and new technology entered the space promising efficiency, while governance lagged behind.

The advantage goes to leaders who connect advocacy insight to execution, align pricing strategy with patient access, and treat transparency as a strategy rather than compliance. I built Archo on a direct belief: when you align business performance with patient impact, you build something that lasts.

Take Your Next Step:

The Advocacy Influence Diagnostic launched in March. If you lead advocacy, market access, or commercial strategy, take five minutes to pressure-test where your function actually stands. The AID measures whether patient voice drives enterprise decisions or decorates slide decks.

The 2026 ELAVAY Report launches in May. ELAVAY remains the only syndicated research measuring how patient advocacy organizations evaluate pharma and biotech companies. If you want to understand your standing before the numbers go public, reach out now.

If you care about protecting patient access at a national level, spend time at wethepatients.org. If your company needs a credible advocacy partner, explore advocatebridge.org.

Email [email protected] or [email protected]. Stay engaged. Stay accountable. Keep the patient at the center.

1   All Sources & Other Artiles of Note by The Author Can Be Found: https://intelligence.archo.io/

1  SOURCE ARTICLES BY PEST CATEGORY

POLICY PULSE:

COST OF CARE:

COMMUNITY LENS:

TECH TRENDS:

Reply

Avatar

or to participate

Keep Reading

© 2026 The Archo Advocate Brief, by Archo Advocacy.
Report abusePrivacy policyTerms of use
beehiivPowered by beehiiv